Click here to link to an introductory slide deck describing Coeurative, Inc. and its lead compounds.
Coeurative, Inc. is a privately owned pharmaceutical development company incorporated in Delaware and operating in Virginia. The company was formed to create and develop curative strategies for the management of cardiovascular and cardiopulmonary diseases associated with cellular hypoxia. The patented compounds developed by Coeurative generate nitric oxide in cells that line the inside of blood vessels, known as endothelial cells. Nitric oxide acts as a vasodilator and a modulator of inflammation.
Cellular hypoxia can be defined as a lack of oxygen at the level of individual cells, not necessarily related to a lack of oxygen at the level of a whole organism or an environment. Most cardiovascular diseases involve a deficiency of oxygen delivery to cells (cellular hypoxia.) Coeurative is developing a new class of pharmaceuticals based on years of scientific research on the regulation of hypoxia-mediated events in blood vessels. The market for products that facilitate long-term management of these conditions will grow along with the population of patients that will benefit from pharmaceuticals.
Heart and blood vessel diseases remain the leading causes of death in the developed world. There are still substantial opportunities for clinical development of small molecule compounds for treatment and prevention. Health care providers point with some pride to the substantial decreases in the death rate due to cardiovascular diseases. The truth is that our success has created a new population of patients: people who used to die of these diseases are now becoming chronic patients in need of long term management. Cardiovascular diseases are growing in prevalence and will continue to be the most significant public health challenge.
The COVID-19 pandemic also calls for new therapeutics. Hypoxia is one of the classic features of COVID-19. Myocardial injury (due to local inflammation and cardiac hypoxia) is strongly correlated with fatal outcomes in COVID-19. Nitric oxide donor compounds can inhibit SARS-coronavirus infection in laboratory experiments.
There are three proposed indications for these compounds that we are working to develop.
The first indication is as an antianginal agent. The compounds are expected to improve exercise capacity in the setting of local hypoxia due to coronary artery disease. These new drugs act as coronary vasodilators through augmented release of endothelial nitric oxide.
The second indication is for secondary prevention of major adverse events associated with endothelial hypoxia in cardiovascular diseases. Nitric oxide donors dilate blood vessels to mitigate hypoxia. We also propose that what is known as ischemic preconditioning can be augmented by these compounds through modulation of vascular inflammatory mediators via the augmented release of endothelial nitric oxide.
The third and latest indication to be developed is that of an anti-viral agent with particular effect on COVID-19 virus (SARS-CoV-2.) Direct anti-viral activity is observed in cell culture and we propose that this is related to specific binding of the compounds to a viral protein as well as an anti-viral effect from targeted nitric oxide release. The patented COEURative compounds, as NO donors, are also proposed as novel anti-viral agents for treatment of COVID-19.
Patent No. US 10,501,471 titled “COMPOUNDS USEFUL FOR TREATING CARDIOVASCULAR DISEASES” was issued on December 10, 2019. Patent No. US 10,913,748 was issued as a continuation patent on February 9, 2021. Recently our filing with the World Intellectual Property Organization was published: PCT – US 2019 058241.
Nonprovisional US Patent Application 17,211,778 and International Patent Application PCT/US21/24540 are also pending.
PLEASE USE THIS FORM FOR CORRESPONDENCE:
John F. Schmedtje Jr., MD
President and CEO
201 McClanahan Street SW
Roanoke, VA 24014
This document is not an offer or agreement to buy or sell securities, or a solicitation of an offer to buy or sell securities. Any such offering or agreement will be made, if at all, pursuant to definitive subscription or other offering materials.